She has something called primary progressive MS and only 10 percent of people with MS have it. Hackensack University Medical Center’s Dr. Florian Thomas says for those patients there wasn’t a treatment available to slow down the disease progression. That was until last year, when the FDA approved the first one, Ocrevus.
READ FULL ARTICLE ON NJTVONLINE.ORG